Product Details

Teva-Budesonide

Budesonide
0.125 mg/mL
Suspension for Inhalation


DIN/PIN/NPN

02465949

Manufacturer

Teva Canada Limited

Formulary Listing Date

2018-04-30  

Unit Price

0.1143

Amount MOH Pays

0.1143

Coverage Status

Limited Use Product

ODB Formulary Therapeutic Classification

Therapeutic Note

NO

ATC Code

R03BA02

Interchangeable Products

DIN/ PIN/ NPN Brand name Unit Price Amount MOH pays
02465949 Teva-Budesonide 0.1143 0.1143
02494264 Taro-Budesonide 0.1143 0.1143
02229099 Pulmicort Nebuamp 0.2657 0.1143
 

LU Clinical Criteria

LU Code Auth. Period Clinical Criteria
Note: For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler.
260 Indefinite

Children aged 6 years or less;

261 Indefinite

Patients who have a tracheostomy;

262 Indefinite

Patients with cystic fibrosis in whom nebulizer therapy is indicated;

263 Indefinite

Patients with severe mental or physical disabilities;

264 Indefinite

Patients who have previously used nebulizer therapy within the last 12-month period.

 

EAP Criteria

NO

Product Monograph

View Monograph